Stryker Launches LITe BIO Bone Graft Delivery System
Stryker has announced the launch of its handheld bone graft delivery system, which provides surgeons with greater visibility and maneuverability, while accommodating the surgeon’s choice of bone graft material. The LITe BIO Delivery System is approved for use in spinal fusion surgeries to deliver autograft, allograft, and synthetic material.
The system — which was approved by the FDA in July — was designed to improve visualization. A radiolucent strip allows surgeons to see under fluoroscopy, and the one-handed, sleeker design allows visibility through a decompression tube. The disposable cannula can hold up to 5 cc of bone graft material, and the system confirms audibly, visually, and tactilely when the graft is successfully placed.
Traditional systems are capable of delivering more than one material but can be cumbersome and difficult to manage during surgery, explained Bradley Paddock, president of Stryker’s spine division, in a press release. Pre-filled options are more streamlined, but limit the surgeon’s choice of material. The LITe Bio System offers all the advanced features of traditional systems with greater simplicity. LITe Bio is also mallet-free, which prevents bone graft impaction.
“Our new LITe BIO Delivery System is innovative in the marketplace, simplifying graft delivery for spine surgeons.” Paddock said. “Its sleek, versatile design can accommodate any bone graft material and provides surgeons with direct visualization to aid in the precise placement of the graft, which is important for optimal fusion. No other system combines all of these key features.”
Stryker has been working to expand its product offerings with a number of acquisitions and tuck-in deals completed this year. Last April, Stryker CEO Kevin Lobo told analysts that the company drove the most value by finding great technologies that further augmented its existing offerings, and that the company would continue to do so in the future.
We “are continuing to scour the market to look for opportunities that will add value,” said Lobo. “And we won’t hesitate to pull the trigger on new deals if we believe they will be value-creating for Stryker.”
Last month, Stryker purchased Instratek and its line of implants and endoscopic instruments. Instratek’s expertise in extremity surgeries furthers Stryker’s commitment to growth in that segment, especially in minimally invasive soft-tissue recession procedures, said David Floyd, group president of orthopedics for Stryker.
Stryker’s acquisition of Ivy Sports Medicine added the market’s only FDA-approved collagen meniscus implant to Stryker’s growing sports medicine business.